KR20240165982A - 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도 - Google Patents

향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도 Download PDF

Info

Publication number
KR20240165982A
KR20240165982A KR1020247034657A KR20247034657A KR20240165982A KR 20240165982 A KR20240165982 A KR 20240165982A KR 1020247034657 A KR1020247034657 A KR 1020247034657A KR 20247034657 A KR20247034657 A KR 20247034657A KR 20240165982 A KR20240165982 A KR 20240165982A
Authority
KR
South Korea
Prior art keywords
disorder
methylone
anxiety
administered
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247034657A
Other languages
English (en)
Korean (ko)
Inventor
블레이크 맨델
마틴 스토그니에우
제니퍼 루이스 슈미트
마르쿠스 실리그
Original Assignee
트랜센드 테라퓨틱스 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2022/074369 external-priority patent/WO2023015154A1/en
Application filed by 트랜센드 테라퓨틱스 인코퍼레이티드 filed Critical 트랜센드 테라퓨틱스 인코퍼레이티드
Publication of KR20240165982A publication Critical patent/KR20240165982A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247034657A 2022-03-31 2023-02-02 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도 Pending KR20240165982A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263325757P 2022-03-31 2022-03-31
US63/325,757 2022-03-31
US202263328343P 2022-04-07 2022-04-07
US63/328,343 2022-04-07
USPCT/US2022/074369 2022-08-01
PCT/US2022/074369 WO2023015154A1 (en) 2021-08-06 2022-08-01 Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US202363437000P 2023-01-04 2023-01-04
US63/437,000 2023-01-04
PCT/US2023/012196 WO2023191952A1 (en) 2022-03-31 2023-02-02 Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders

Publications (1)

Publication Number Publication Date
KR20240165982A true KR20240165982A (ko) 2024-11-25

Family

ID=88203364

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247034657A Pending KR20240165982A (ko) 2022-03-31 2023-02-02 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도

Country Status (10)

Country Link
EP (1) EP4499066A4 (https=)
JP (1) JP2025510790A (https=)
KR (1) KR20240165982A (https=)
CN (1) CN119095593A (https=)
AU (1) AU2023241546A1 (https=)
CA (1) CA3254727A1 (https=)
IL (1) IL315832A (https=)
MX (1) MX2024012095A (https=)
TW (1) TW202345789A (https=)
WO (1) WO2023191952A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120379978A (zh) * 2022-10-20 2025-07-25 创见疗法股份有限公司 苯乙胺和卡西酮及其立体异构体与其前体的制备

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039133A1 (en) * 1995-06-06 1996-12-12 Neurobiological Technologies, Inc. Novel n-substituted-2-amino-3',4'-methylene-dioxypropiophenones
US8575194B1 (en) * 2004-08-31 2013-11-05 Jack William Schultz Treatment methods of cognitive, emotional and mental ailments and disorders
EP2931291B1 (en) * 2012-12-11 2021-10-20 The McLean Hospital Corporation Xenon treatment as an adjunct to psychotherapy for psychiatric disorders
WO2017151980A1 (en) * 2016-03-03 2017-09-08 Segreti Louis M Cannabis-based bioactive formulations and methods for use thereof
WO2021257500A1 (en) * 2020-06-17 2021-12-23 Lobe Sciences Ltd. Methods and compositions for treating mild traumatic brain injury, post-traumatic stress disorder and mild traumatic brain injury with post traumatic stress disorder
JP2024512796A (ja) * 2021-04-01 2024-03-19 テラン バイオサイエンシーズ インク． サイケデリック薬およびセロトニン受容体調節因子に関する方法と組成物
MX2024001654A (es) * 2021-08-06 2024-06-28 Transcend Therapeutics Inc Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiatricos y neurologicos.
AU2022330718B2 (en) * 2021-08-20 2026-02-19 Pharmala Biotech Inc. Compositions comprising non-racemic mixtures of (r)- and (s)-3,4-methylenedioxymethamphetamine or (r) and (s) n-methyl-1,3-benzodioxolylbutanamine and uses thereof
WO2023081899A1 (en) * 2021-11-05 2023-05-11 Terran Biosciences, Inc. Isotopically enriched n-methyl-1,3-benzodioxolylbutanamine (mbdb) and stereoisomers thereof
EP4426685A4 (en) * 2021-11-05 2026-01-07 Terran Biosciences Inc Isotopic salts, crystalline forms, stereoisomers of methylone and ethylone and their methods of use
CA3239514A1 (en) * 2021-12-09 2023-06-15 Matthew J. Baggott Specialized combinations for mental disorders or mental enhancement

Also Published As

Publication number Publication date
MX2024012095A (es) 2025-01-09
IL315832A (en) 2024-11-01
CN119095593A (zh) 2024-12-06
WO2023191952A1 (en) 2023-10-05
CA3254727A1 (en) 2023-10-05
JP2025510790A (ja) 2025-04-15
TW202345789A (zh) 2023-12-01
EP4499066A4 (en) 2026-02-18
AU2023241546A1 (en) 2024-10-17
EP4499066A1 (en) 2025-02-05

Similar Documents

Publication Publication Date Title
US12377112B2 (en) Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
US12059402B2 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
EA012036B1 (ru) Мемантин для лечения расстройств поведения детского возраста
EP2968220B1 (en) Methods and compositions for improving cognitive function
TW202306571A (zh) 確定待投與於個體的致幻劑之劑量或與另一種致幻劑之劑量等效性之方法
KR20240165982A (ko) 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도
US20250221957A1 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US12295937B2 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US12343326B2 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US20250332139A1 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
HK40120411A (zh) 精神作用药物及其用於治疗精神和神经病状和病症的用途
WO2024254190A2 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
AU2024284688A1 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
HK40112015A (zh) 精神作用药物及其用於治疗精神和神经病状和病症的用途
KR20260053276A (ko) 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도
CN118434416A (zh) 精神作用药物及其用于治疗精神和神经病状和病症的用途
HK40068315A (en) Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
HK1220364B (en) Methods and compositions for improving cognitive function

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000